Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05809531 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Study acronym: VALE
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 1 of 47 sitesv6
  2. Re-verified, no change to tracked fieldsv5
  3. Study sites: 26 to 47v4
  4. Trial status: Not Yet Recruiting to Active, Not Recruiting Study sites: 0 to 26 · Start date changed from estimate of May 2023 to May 29, 2023v3 Show 2 more changesShow less
    • Study sites: 0 to 26
    • Start date changed from estimate of May 2023 to May 29, 2023
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is designed as a long-term extension to Study APL2-C3G-310, and is being conducted to establish the long-term safety and efficacy of pegcetacoplan in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN).
Trial Details
NCT Number NCT05809531
Lead Sponsor Apellis Pharmaceuticals, Inc.
Conditions C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease +4 more
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov